Bortezomib-associated late hepatitis B reactivation in a case of multiple myeloma

References (7)

1. Tong Y, Qian J, Li Y, et al. The high incidence of varicella herpes zoster with the use of bortezomib in 10 patients. Am J Hematol 2007; 82: 403-4
2. Ifran A, Beyan C, Kaptan K. Development of zona zoster during bortezomib treatment in patients with relapsed/refractory multiple myeloma. Turk J Hematol 2008; 25: 1034
3. Orciuolo E, Galimberti S, Petrini M. Bortezomib inhibits Tcell function versus infective antigenic stimuli in a dose-dependent manner in vitro. Leuk Res 2007; 31: 1026-7
4. Wu KL, Van Wieringen W, Vellenga E, et al. Analysis of the efficacy and toxicity of bortezomib for treatment of relapsed or refractory multiple myeloma in community practice. Haematologica 2005; 90: 996-7
5. Rosinol L, Montoto S, Ciberia MT, Blade J. Bortezomib-induced severe hepatitis in multiple myeloma. Arch Intern Med 2005; 165: 464-5
6. Menashe J. Managing and avoiding bortezomib toxicity. Commun Oncol 2007; 4: 480-4
7. Vickrey E, Allen S, Mehta J, Singhal S. Acyclovir to prevent reactivation of varicella zoster virus (herpes zoster) in multiple myeloma patients receiving bortezomib therapy. Cancer 2009; 115: 229-32.